パイプライン
弊社の臨床開発パイプラインと進行中の試験については、以下をご覧ください。
開発プログラム - 固形腫瘍
薬剤
適応症
第1相
第2相
第3相
チスレリズマブ
(PD-1 mAb)
1L NonSq NSCLC
1L Sq NSCLC
2/3L NSCLC
Neo/adj NSCLC（ネオアジュバント/アジュバントNSCLC）
1L ES-SCLC
1L ESCC
2L ESCC
LA ESCC
1L GC/GEJC
1L NPC
1L HCC
1L UBC
2/3L HCC
1L NSCLC (subcutaneous formulation)
オシペルリマブ
(TIGIT mAb)
1L PD-L1 高NSCLC
NSCLC dose confirmation
BG-685011
（CDK2阻害剤）
BC及び固形腫瘍
BGB-43395
（CDK4阻害剤）
BC及び固形腫瘍
BG-C90742
(B7H4 ADC)
BC及び固形腫瘍
BGB-C354
(B7H3 ADC)
固形腫瘍
LBL-0073
(LAG3 mAb)
MSS-CRC
1L ESCC
Umbrellaa
（免疫療法の組み合わせ）
1L NSCLC
Neo/adj NSCLC（ネオアジュバント/アジュバントNSCLC）
2L+ NSCLC
1L HNSCC
ザニダタマブ4
(HER2 BsAb)
2L HER2+ BTC
1L HER2+ GEA
BGB-A445
(OX40 mAb)
Melanoma, UC
BGB-15025
（HPK1阻害剤）
固形腫瘍
BGB-26808
（HPK1阻害剤）
固形腫瘍
BGB-24714
（SMAC模倣薬）
固形腫瘍
BGB-30813
（DGKζ阻害剤）
固形腫瘍
BGB-A3055
(CCR8 mAb)
固形腫瘍
パミパリブ
（PARP 1/2阻害剤）
2L MTx gBRCAm PSOC
タルラタマブ5
(DLL3 x CD3 BsAb)
2L SCLC
1L ES-SCLC
LS-SCLC
3L+ SCLC
ザルリタミグ5
(STEAP1 x CD3 BsAb)
mCRPC
BGB-R046
(IL-15 prodrug)
固形腫瘍
BGB-B3227
（MUC1 x CD16A BsAb）
固形腫瘍
BGB-B2033
(GPC3 x 4-1BB BsAb)
固形腫瘍
BG-T187†
(EGFR x MET TsAb)
固形腫瘍
BG-C137†
（FGFR2b ADC）
固形腫瘍
BGB-53038†
(PanKRAS inhibitor)
固形腫瘍
BGB-58067†
（PRMT5阻害剤）
固形腫瘍
BG-C477
(CEA ADC)
固形腫瘍
治験薬および/またはその用途に関する安全性および有効性は立証されていません。
開発プログラム-血液学的検査
薬剤
適応症
第1相
第2相
第3相
ザヌブルチニブ
（BTK阻害剤）
CLL/SLL
WM
R/R FL
R/R MZL
TN MCL
再発性／抵抗性MCL
再発性／抵抗性びまん性大細胞型B細胞性リンパ腫（CD79Bあり）
前治療歴のあるB細胞性悪性腫瘍
sonrotoclax
（BCL2 阻害剤）
TN CLLb
R/R WM
R/R CLL
再発性／抵抗性MCL
TN CLL/SLL †
R/R MM with t(11;14)
AML/MDS
B細胞性悪性腫瘍
BGB-16673
(BTK標的CDAC）
B細胞性悪性腫瘍
B-cell malignancies†
R/R MCL及びR/R CLL
BGB-21447
(next gen BCL2 inhibitor)
B細胞性悪性腫瘍
チスレリズマブ
(PD-1 mAb)
R/R cHL
オシペルリマブ
(TIGIT mAb)
R/R DLBCL
ザヌブルチニブ
（BTK阻害剤）
原発性膜性腎症
ループス腎炎
BGB-45035
(IRAK4 CDAC)
Immunology & inflammation
ブリナツモマブ5
(CD3 x CD19 BsAb)
Pediatric R/R BP-ALL
治験薬および/またはその用途に関する安全性および有効性は立証されていません。
aMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor.
bin combination with zanubrutinib.
†Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.
1Ensemと提携。BeiGeneが全世界での権利を保有。
2DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights.
3Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China.
4Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand.
5Amgen collaboration; BeiGene has development and commercialization rights in China.
1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; AML, acute myeloid leukemia; BC, breast cancer; BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD16A, Fc receptor FcγRIIIa; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK2, cyclin-dependent kinase 2; CDK4, cyclin-dependent kinase 4; CEA, carcinoembryonic antigen; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FL, follicular lymphoma; gBRCAm, germline BReast CAncer gene (BRCA) mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; IRAK4, interleukin-1 receptor-associated kinase 4; KRAS, Kirsten rat sarcoma virus; LA, locally advanced; mAb, monoclonal antibody; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mAb, monoclonal antibody; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MUC1, mucin 1; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; STEAP1, six-transmembrane epithelial antigen of the prostate 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; TsAb, trispecific antibody; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.
インタラクティブな臨床パイプライン
ビデオ
抗OX40の作用機序
抗PD-1の作用機序
CDK4阻害剤の作用機序
BTKIの作用機序
抗TIGITの作用機序
PARPIの作用機序
